These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 29447488)

  • 1. Long-term effects of Lee Silverman Voice Treatment on daily voice use in Parkinson's disease as measured with a portable voice accumulator.
    Körner Gustafsson J; Södersten M; Ternström S; Schalling E
    Logoped Phoniatr Vocol; 2019 Oct; 44(3):124-133. PubMed ID: 29447488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
    Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
    Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
    Wight S; Miller N
    Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voice Use in Daily Life Studied With a Portable Voice Accumulator in Individuals With Parkinson's Disease and Matched Healthy Controls.
    Gustafsson JK; Södersten M; Ternström S; Schalling E
    J Speech Lang Hear Res; 2019 Dec; 62(12):4324-4334. PubMed ID: 31830844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
    Sackley CM; Rick C; Brady MC; Woolley R; Burton C; Patel S; Masterson-Algar P; Nicoll A; Smith CH; Jowett S; Ives N; Beaton G; Dickson S; Ottridge R; Sharp L; Nankervis H; Clarke CE;
    BMJ; 2024 Jul; 386():e078341. PubMed ID: 38986549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Hypophonia in Parkinson's Disease Through Biofeedback in Daily Life Administered with A Portable Voice Accumulator.
    Gustafsson JK; Södersten M; Ternström S; Schalling E
    J Voice; 2024 May; 38(3):800.e27-800.e38. PubMed ID: 34893384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Portable Voice Accumulators to Study Transfer of Speech Outcomes Following Intervention - A Feasibility Study.
    Steurer H; Körner Gustafsson J; Franzén E; Schalling E
    J Voice; 2024 Jul; 38(4):965.e1-965.e13. PubMed ID: 34852954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effects of intensive voice treatment (LSVT LOUD
    Boliek CA; Fox CM
    Int J Speech Lang Pathol; 2017 Dec; 19(6):601-615. PubMed ID: 27705010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectral/Cepstral Analyses of Phonation in Parkinson's Disease before and after Voice Treatment: A Preliminary Study.
    Alharbi GG; Cannito MP; Buder EH; Awan SN
    Folia Phoniatr Logop; 2019; 71(5-6):275-285. PubMed ID: 31117110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy.
    Sale P; Castiglioni D; De Pandis MF; Torti M; Dall'armi V; Radicati FG; Stocchi F
    Eur J Phys Rehabil Med; 2015 Oct; 51(5):569-74. PubMed ID: 26138088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.
    Ramig LO; Sapir S; Countryman S; Pawlas AA; O'Brien C; Hoehn M; Thompson LL
    J Neurol Neurosurg Psychiatry; 2001 Oct; 71(4):493-8. PubMed ID: 11561033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor-Learning-Based Adjustment of Ambulatory Feedback on Vocal Loudness for Patients With Parkinson's Disease.
    Gustafsson J; Ternström S; Södersten M; Schalling E
    J Voice; 2016 Jul; 30(4):407-15. PubMed ID: 26168903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT
    Ertan E; Gürvit HI; Hanağası HH; Bilgiç B; Tunçer MA; Yılmaz C
    Logoped Phoniatr Vocol; 2022 Dec; 47(4):262-270. PubMed ID: 34287100
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on ataxic dysarthria: a case study.
    Sapir S; Spielman J; Ramig LO; Hinds SL; Countryman S; Fox C; Story B
    Am J Speech Lang Pathol; 2003 Nov; 12(4):387-99. PubMed ID: 14658991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the LSVT on vowel articulation and coarticulation in Parkinson's disease.
    Sauvageau VM; Roy JP; Langlois M; Macoir J
    Clin Linguist Phon; 2015 Jun; 29(6):424-40. PubMed ID: 25688915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversational Vocal Intensity in Parkinson's Disease: Treatment and Environmental Comparisons.
    Konnai R; Van Harn M; Silbergleit A
    J Voice; 2023 Sep; 37(5):707-715. PubMed ID: 34134903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.